Vedolizumab: Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: case report
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Fields of Study & Subjects
Cutaneous lymphoproliferative disorders research
Drug-Induced Adverse Reactions
Dermatology and Skin Diseases
Publication details
- Journal / source
- Reactions Weekly
- Volume
- 2103
- Issue
- 1
- Pages
- 198–198
- Publication date
- 26 March 2026
- Language
- EN